On this page

Betamethasone Valerate

Prescription NDA TE AB Official labelling
Informational index, not medical advice. Content is reproduced from public FDA and NLM data. Always confirm against the manufacturer's current prescribing information. Report adverse events to FDA MedWatch.

Overview

Brand name
Betamethasone Valerate
Generic name
Betamethasone Valerate
Dosage form
Cream
Route
Topical
Marketing category
NDA · NDA
Labeler
A-S Medication Solutions
Product type
Human Prescription Drug
DEA schedule
Not scheduled
Active ingredients
2
NDC product codes
12
Packages
17
Data completeness
82% of corroborating sources present

Active ingredients

Source: NDC Directory
Active ingredients and strengths as listed in the NDC Directory.
Ingredient Strength RxCUI Monograph
Betamethasone Valerate 1 mg/g 197407 View
Betamethasone Valerate 1.2 mg/g 197407 View

Forms, strengths and routes

Source: NDC Directory
Dosage form
Cream
Route of administration
Topical
Presentations
29

Pharmacologic classes are listed in the class section below.

Pharmacologic class

Source: NDC Directory
Established pharmacologic classes (EPC), mechanisms of action (MoA), chemical structures (CS) and physiologic effects (PE).
Class Type Browse
Corticosteroid Hormone Receptor Agonists [MoA] MoA All 215 members
Corticosteroid [EPC] EPC All 215 members

Regulatory status

Source: Drugs@FDANDC Directory
Application number
072041
Application type
NDA · New Drug Application
Approval date
January 6, 1988
Sponsor
SUN PHARMA CANADA
Products on application
1
Submissions recorded
11
Products approved under application 072041.
Product Trade name Form Strength Ingredient Status TE Flags
072041-001 DERMABET CREAM BETAMETHASONE VALERATE Prescription AB

Therapeutic equivalence

Source: Orange Book
TE code
AB
Reference Listed Drug
No
Reference Standard
No

What this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing

Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.

Approval history

Source: Drugs@FDA
Most recent submissions on application 072041.
Type No. Action Status Date Review
Supplement 23 Labeling Approved March 22, 2017 Standard
Supplement 11 Labeling Approved September 27, 2004 —
Supplement 8 Manufacturing (CMC) Approved July 11, 2001 —
Supplement 5 Manufacturing (CMC) Approved October 23, 2000 —
Supplement 7 Manufacturing (CMC) Approved April 8, 1999 —
Supplement 6 Manufacturing (CMC) Approved October 20, 1998 —
Supplement 4 Manufacturing (CMC) Approved September 17, 1996 —
Supplement 3 Manufacturing (CMC) Approved May 14, 1996 —
Supplement 2 Manufacturing (CMC) Approved March 24, 1989 —
Supplement 1 Manufacturing (CMC) Approved December 9, 1988 —
Original application 1 Approved January 6, 1988 —

Prescribing information

Source: openFDA Drug Labeling

Reproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260204). This is the manufacturer's labelling text, not a summary and not advice.

HUMAN PRESCRIPTION DRUG · 20260204 HUMAN PRESCRIPTION DRUG · 20250207 HUMAN PRESCRIPTION DRUG · 20220601 HUMAN PRESCRIPTION DRUG · 20220505

Indications and Usage

openFDA Drug Labeling

INDICATIONS AND USAGE: Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

Dosage and Administration

openFDA Drug Labeling

DOSAGE AND ADMINISTRATION: Apply a thin film of Betamethasone Valerate Cream or Ointment to the affected skin areas one to three times a day. Dosage once or twice a day is often effective. Apply a few drops of Betamethasone Valerate Lotion to the affected area and massage lightly until it disappears. Apply twice daily, in the morning and at night. Dosage may be increased in stubborn cases. Following improvement, apply once daily. For the most effective and economical use, apply nozzle very close to affected area and gently squeeze bottle.

Contraindications

openFDA Drug Labeling

CONTRAINDICATIONS: Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Adverse Reactions

openFDA Drug Labeling

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc., at 1-866-923-4914 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Description

openFDA Drug Labeling

DESCRIPTION: Betamethasone Valerate Cream, Ointment and Lotion contain betamethasone valerate USP, a synthetic adrenocorticosteroid for dermatologic use. Betamethasone, an analog of prednisolone, has a high degree of glucocorticoid activity and a slight degree of mineralocorticoid activity. Betamethasone valerate is a white to practically white odorless crystalline powder practically insoluble in water, freely soluble in acetone and chloroform, soluble in alcohol, and slightly soluble in benzene and ether. Chemically, it is 9-fluoro-11β,17,21-trihydroxy-16β-methylpregna-1, 4-diene-3,20-dione 17-valerate. The structural formula is: Each gram of the 0.1% Cream contains 1.2 mg betamethasone valerate (equivalent to 1 mg betamethasone) in a soft, white, hydrophilic cream of purified water, mineral oil, white petrolatum, polyethylene glycol 1000 monocetyl ether, cetostearyl alcohol, monobasic sodium phosphate and phosphoric acid or sodium hydroxide (to adjust pH, if required); chlorocresol is present as a preservative. Each gram of the 0.1% Ointment contains 1.2 mg betamethasone valerate (equivalent to 1 mg betamethasone) in an ointment base of white petrolatum and mineral oil. Each gram of the 0.1% Lotion contains 1.2 mg betamethasone valerate (equivalent to 1 mg betamethasone) in a vehicle of isopropyl alcohol and water slightly thickened with carbomer 934P. Sodium hydroxide is used to adjust pH. structural formula

OVERDOSAGE: Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS ).

How Supplied / Storage and Handling

openFDA Drug Labeling

HOW SUPPLIED Betamethasone Valerate Cream USP, 0.1% is supplied as follows: 15 g tubes NDC 0713-0326-15 45 g tubes NDC 0713-0326-37 Betamethasone Valerate Ointment USP, 0.1% is supplied as follows: 15 g tubes NDC 0713-0327-15 45 g tubes NDC 0713-0327-37 Store at room temperature 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Distributed by: Cosette Pharmaceuticals, Inc. South Plainfield, NJ 07080 Rev. 03/2022 8-BETVCPLNC3 VC7618

Adverse event reports

Source: openFDA FAERS
4,509
FAERS reports mentioning this drug
as of 2026-09-25T03:42:24+00:00
A report count is not a risk measure. FAERS accepts voluntary and mandatory reports without establishing causation, and reporting is influenced by how widely a drug is used, how long it has been marketed, and media attention. FDA states that reports “do not prove that the drug caused the event”. Compare rates, not totals.

Attributed to this product's most-reported active ingredient: BETAMETHASONE VALERATE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.

Packaging and NDCs

Source: NDC Directory
Every National Drug Code package associated with this medication. The NDC is the identifier used for dispensing, billing and pharmacovigilance in the United States.
Package NDC Product NDC Labeler Description Marketing start
50090-1647-0 50090-1647 A-S Medication Solutions 1 TUBE in 1 CARTON (50090-1647-0) / 15 g in 1 TUBE January 19, 2015
50090-3134-1 50090-3134 A-S Medication Solutions 1 TUBE in 1 CARTON (50090-3134-1) / 45 g in 1 TUBE September 8, 2017
50090-3794-1 50090-3794 A-S Medication Solutions 1 TUBE in 1 CARTON (50090-3794-1) / 45 g in 1 TUBE November 8, 2018
50090-4696-0 50090-4696 A-S Medication Solutions 1 TUBE in 1 CARTON (50090-4696-0) / 15 g in 1 TUBE November 7, 2019
0713-0326-15 0713-0326 Cosette Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (0713-0326-15) / 15 g in 1 TUBE August 27, 2015
0713-0326-37 0713-0326 Cosette Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (0713-0326-37) / 45 g in 1 TUBE August 27, 2015
0168-0040-15 0168-0040 E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC 15 g in 1 TUBE (0168-0040-15) August 31, 1983
0168-0040-46 0168-0040 E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC 45 g in 1 TUBE (0168-0040-46) August 31, 1983
68071-4278-5 68071-4278 NuCare Pharmaceuticals,Inc. 15 g in 1 BOX (68071-4278-5) February 8, 2018
68071-5224-5 68071-5224 NuCare Pharmaceuticals,Inc. 15 g in 1 BOX (68071-5224-5) March 30, 2020
68788-8450-1 68788-8450 Preferred Pharmaceuticals Inc. 15 g in 1 TUBE (68788-8450-1) May 26, 2023
68788-8450-4 68788-8450 Preferred Pharmaceuticals Inc. 45 g in 1 TUBE (68788-8450-4) May 26, 2023
68788-7451-1 68788-7451 Preferred Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (68788-7451-1) / 15 g in 1 TUBE January 31, 2019
68788-7451-4 68788-7451 Preferred Pharmaceuticals, Inc. 1 TUBE in 1 CARTON (68788-7451-4) / 45 g in 1 TUBE January 31, 2019
71205-040-15 71205-040 Proficient Rx LP 15 g in 1 TUBE (71205-040-15) May 1, 2018
51672-1269-1 51672-1269 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1269-1) / 15 g in 1 TUBE January 6, 1988
51672-1269-6 51672-1269 Sun Pharmaceutical Industries, Inc. 1 TUBE in 1 CARTON (51672-1269-6) / 45 g in 1 TUBE January 6, 1988
50090-1647 50090-1647 A-S Medication Solutions — January 6, 1988
50090-3134 50090-3134 A-S Medication Solutions — January 6, 1988
50090-3794 50090-3794 A-S Medication Solutions — March 24, 1983
50090-4696 50090-4696 A-S Medication Solutions — March 24, 1983
0713-0326 0713-0326 Cosette Pharmaceuticals, Inc. — March 24, 1983
0168-0040 0168-0040 E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC — August 31, 1983
68071-4278 68071-4278 NuCare Pharmaceuticals,Inc. — January 6, 1988
68071-5224 68071-5224 NuCare Pharmaceuticals,Inc. — March 24, 1983
68788-8450 68788-8450 Preferred Pharmaceuticals Inc. — May 26, 2023
68788-7451 68788-7451 Preferred Pharmaceuticals, Inc. — January 6, 1988
71205-040 71205-040 Proficient Rx LP — August 31, 1983
51672-1269 51672-1269 Sun Pharmaceutical Industries, Inc. — January 6, 1988

Sources for this page

Every dataset that contributed a fact to this page.
Dataset Agency Used for
NDC Directory FDA Identity, ingredients, strengths, forms, routes, labelers, packages
Drugs@FDA FDA Application, sponsor, submissions, review documents, marketing status
Orange Book FDA Therapeutic equivalence codes, reference drug flags, patents, exclusivity
Drug Labeling FDA / NLM Prescribing information reproduced above
FAERS FDA Adverse event report counts

Generated September 25, 2026 · 12 sections on this page.